Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Anne de Roquancourt"'
Autor:
Sylvie Giacchetti, Lilith Faucheux, Charlotte Gardair, Caroline Cuvier, Anne de Roquancourt, Luca Campedel, David Groheux, Cedric de Bazelaire, Jacqueline Lehmann-Che, Catherine Miquel, Laurence Cahen Doidy, Malika Amellou, Isabelle Madelaine, Fabien Reyal, Laetitia Someil, Hamid Hocini, Christophe Hennequin, Luis Teixeira, Marc Espié, Sylvie Chevret, Vassili Soumelis, Anne-Sophie Hamy
Publikováno v:
Cancers, Vol 14, Iss 5, p 1331 (2022)
Background: Patients with triple-negative breast cancers (TNBC) have a poor prognosis unless a pathological complete response (pCR) is achieved after neoadjuvant chemotherapy (NAC). Few studies have analyzed changes in TIL levels following dose-dense
Externí odkaz:
https://doaj.org/article/3d871d9fd6c34ebda54454444faf6100
Autor:
Luca Campedel, Paul Blanc-Durand, Asker Bin Asker, Jacqueline Lehmann-Che, Caroline Cuvier, Cedric De Bazelaire, Luis Teixeira, Stephanie Becourt, Florence Ledoux, Hamid Hocini, Edwige Bourstyn, Catherine Miquel, Sophie Guillerm, Patrick Charveriat, Marc Espié, Anne De Roquancourt, Anne-Sophie Hamy, Sylvie Giacchetti
Publikováno v:
Cancers, Vol 12, Iss 9, p 2657 (2020)
Inflammatory breast cancers are very aggressive, and among them, triple negative breast cancer (TNBC) has the worst prognosis. While many studies have investigated the association between tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemot
Externí odkaz:
https://doaj.org/article/66dca1dc8eae4ee3b23152ea9d00b719
Publikováno v:
Analytical Cellular Pathology, Vol 20, Iss 2-3, Pp 83-91 (2000)
Tumour progression is currently believed to result from genetic instability. Chromosomal patterns specific of a type of cancer are frequent even though phenotypic spatial heterogeneity is omnipresent. The latter is the usual cause of histological gra
Externí odkaz:
https://doaj.org/article/e8e4043d10a84e8786d215e477f68498
Autor:
Philippe Bertheau, Elisabeth Turpin, David S Rickman, Marc Espié, Aurélien de Reyniès, Jean-Paul Feugeas, Louis-François Plassa, Hany Soliman, Mariana Varna, Anne de Roquancourt, Jacqueline Lehmann-Che, Yves Beuzard, Michel Marty, Jean-Louis Misset, Anne Janin, Hugues de Thé
Publikováno v:
PLoS Medicine, Vol 4, Iss 3, p e90 (2007)
BackgroundIn breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification of markers that could predict the response to a particular regimen would thus be critically important for
Externí odkaz:
https://doaj.org/article/bd6f9a108f7045788699dc97bf36fc6a
Autor:
Philippe Bertheau, Charlotte Gardair, Laurence Cahen-Doidy, Patrick Charveriat, Philippe Drabent, Anne de Roquancourt
Publikováno v:
Annales de Pathologie
Annales de Pathologie, Elsevier Masson, 2019, 39, pp.9-13. ⟨10.1016/j.annpat.2018.07.004⟩
Annales de Pathologie, Elsevier Masson, 2019, 39, pp.9-13. ⟨10.1016/j.annpat.2018.07.004⟩
Resume La reconnaissance des metastases mammaires par le pathologiste est fondamentale car leur pronostic et leur traitement sont differents de ceux des carcinomes mammaires primitifs. Nous rapportons l’observation d’une patiente de 54 ans presen
Autor:
Anne-Sophie Hamy, Amyn Kassara, Hamid Hocini, Clementine Garin, Luis Teixeira, Caroline Cuvier, Paul Gougis, Elise Dumas, Fabien Reyal, Beatriz Grandal, Nadir Sella, Eric Daoud, Aurélien Latouche, Thierry Dubois, Annabelle Ballesta, Samar Alsafadi, Elaine Del Nery, Élodie Anthony, Benjamin Marande, Cedric de Bazelaire, Anne de Roquancourt, Catherine Michel, Sylvie Giacchetti, Marc Espie
Publikováno v:
Cancer Research. 82:3348-3348
Context: There is a growing interest in drug repurposing and pathological complete response (pCR) that may influence the progression and treatment of breast cancer (BC). However, few studies focus on the influence of comedications, i.e., non-anticanc
Autor:
Stéphanie Bécourt, Florence Ledoux, Patrick Charveriat, Paul Blanc-Durand, Luis Augusto Teixeira, Jacqueline Lehmann-Che, E. Bourstyn, Sophie Guillerm, Cédric de Bazelaire, Luca Campedel, Anne de Roquancourt, Catherine Miquel, Caroline Cuvier, Sylvie Giacchetti, H. Hocini, Anne-Sophie Hamy, M. Espie, Asker Bin Asker
Publikováno v:
Cancers
Cancers, MDPI, 2020, 12 (9), pp.2657. ⟨10.3390/cancers12092657⟩
Cancers, Vol 12, Iss 2657, p 2657 (2020)
Volume 12
Issue 9
Cancers, MDPI, 2020, 12 (9), pp.2657. ⟨10.3390/cancers12092657⟩
Cancers, Vol 12, Iss 2657, p 2657 (2020)
Volume 12
Issue 9
Inflammatory breast cancers are very aggressive, and among them, triple negative breast cancer (TNBC) has the worst prognosis. While many studies have investigated the association between tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c67144cde11a07fc6652c48f0431a2a9
https://hal.sorbonne-universite.fr/hal-02953932
https://hal.sorbonne-universite.fr/hal-02953932
Autor:
Luis Augusto Teixeira, Sylvie Giacchetti, Lucie Biard, Laetitia Vercellino, Anne de Roquancourt, Patricia de Cremoux, Pascal Merlet, David Groheux, Caroline Cuvier, Elif Hindié, Matthieu Resche-Rigon, Marc Espié
Publikováno v:
Journal of Nuclear Medicine. 57:536-543
Patients with triple-negative breast cancer (TNBC) have poor outcome when pathologic complete response (pCR) is not reached after neoadjuvant chemotherapy. Early prediction would be helpful. We evaluated the association between metabolic response aft
Autor:
Charlotte, Gardair, Philippe, Drabent, Patrick, Charveriat, Philippe, Bertheau, Laurence, Cahen-Doidy, Anne, de Roquancourt
Publikováno v:
Annales de pathologie. 39(1)
Recognition of mammary metastases by pathologists is fundamental because their prognosis and treatment are different from those of primary mammary carcinomas. We report the case of a 54-year-old woman presenting on her mammography a left breast nodul
Autor:
Frédérique Penault-Llorca, Roman Rouzier, Xavier Pivot, Christophe Pomel, Jean-Louis Misset, Philippe Rouanet, Rémy Largillier, Herve L. Naman, Joseph Gligorov, Dominique Spaeth, Anne de Roquancourt, J.-L. Sautière, William Jacot
Publikováno v:
Oncologist
Oncologist, 2015, 20 (8), pp.873-879. ⟨10.1634/theoncologist.2014-0467⟩
Oncologist, AlphaMed Press, 2015, 20 (8), pp.873-879. ⟨10.1634/theoncologist.2014-0467⟩
Oncologist, 2015, 20 (8), pp.873-879. ⟨10.1634/theoncologist.2014-0467⟩
Oncologist, AlphaMed Press, 2015, 20 (8), pp.873-879. ⟨10.1634/theoncologist.2014-0467⟩
Background. The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting. The choice of adjuvant treatments